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The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance
who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for
63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an
antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLinkHealth Plan Claims
Database.The expected number of cancer cases in the general population for each gender-age group (<30, 30–39, 40–49, 50–59, and
>60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized
incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence
rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74–48.94), non-Hodgkin lymphoma (4.22;
3.63–4.45), Hodgkin lymphoma (9.83; 7.45–10.84), and anal cancer (30.54; 25.62–32.46) and lower for colorectal cancer (0.69; 0.52–
0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45–0.58). Commercially insured, treated HIV-infected adults had
elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.
1. Introduction
With the widespread use of highly active antiretroviral
therapy (HAART), the life expectancy of HIV-infected per-
sons in the United States has increased markedly [1]. HIV-
infected persons are at higher risk for cancer compared
with the general population [2, 3]. Utilization of highly
active antiretroviral therapy (HAART) has been associated
with decreased incidence rates for AIDS-defining cancers
(ADCs) among HIV-infected persons [4, 5], but its impact
on non-AIDS-defining cancers (NADCs) has been mixed
[6–8]. An elevated risk of anal cancer [9, 10] and Hodgkin
lymphoma (HL) has been observed among HAART users
[11, 12]. After adjusting for CD4+ cell count and HIV viral
load, a relationship betweenduration of antiretroviral therapy
and incidence of NADCs was not observed in a cohort study
of HIV-infected adults [10].
In the general population, health insurance coverage
has been associated with lower mortality rates [13] and
higher utilization of cancer prevention measures such as
screening procedures [14] and HPV vaccine uptake [15].
Among adults between 18 and 65 years of age in 2007, 67%had
private insurance, mostly through their employers, 14% were
covered byMedicaid, and 17%were uninsured [16]. Insurance
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coverage varied by educational level and geographic region
[16]. Among adults, 28.0% of those who had not completed
high school had private insurance compared with 53.9%
with a high school degree or equivalent and 75.2% of those
who pursued postsecondary education [16]. Private health
coverage was reported by 60–62% of those in the West and
South and 66–68% of those in the Midwest and East [16].
Reports vary on the health insurance coverage among
HIV-infected persons. In the Medical Monitoring Project of
HIV-infected persons who soughtmedical care in 2009, 81.1%
had some insurance coverage and 30.6% were covered by
private insurance over the preceding 12 months [17]. In a
study of men who have sex with men (MSM) conducted in 21
metropolitan areas by the National HIV Behavioral Surveil-
lance System, 75% of participants had current health insur-
ance and 39% were solely covered by private insurance [18].
Among HIV-infected persons, factors associated with
private insurance were white race, female gender, men who
have sex with men, and having less than two CD4+ counts
measures of ≤200 cells/mm3 in the preceding year [19]. Risk
factors and receipt of health care are related to health insur-
ance coverage among HIV-infected persons. Commercially
insured patients initiated antiretroviral therapy at an earlier
stage of their disease defined by CD4+ cell counts than those
onMedicaid [20]. Inpatient hospitalizations occurred less fre-
quently among HIV-infected patients with private insurance
compared to those who were uninsured or who had other
insurance [19]. HIV-infected MSM with private insurance
were less likely to miss primary HIV care appointments than
those without insurance [21].
While use of antiretroviral therapy and health care
coverage are beneficial for the management of HIV, the
implications are unclear with respect to development of
cancer. The objective of this study was to explore the inci-
dence of cancer among commercially insured HIV-infected
individuals receiving antiretroviral therapy.
2. Materials and Methods
The source of the data for this study was the LifeLink
Health Plan Claims Database of paid insurance claims data
from managed care plans and other sources in the United
States. The full database includes information on over 73
million persons from over 80 commercial health care plans
in the US. The database includes duration of participation
on a health care plan from enrollment date or first claim
date to termination date or last claim date, gender, age at
enrollment, geographic region of residence, and insurance
claims information. Geographic regions were defined based
on the US Census Bureau Regions.
From this database, we obtained the paid health insurance
claims for 65,341 individuals who had at least one claim
with an ICD-9-CM diagnostic code for HIV (042, V08, or
079.53) and at least one filled prescription for an antiretroviral
medication between January 1, 2006, and September 30, 2012.
We excluded persons under 18 years of age, those for whom
gender information was missing, and those for whom the
initial claim date for HIV was after plan termination. Thus,
63,221 unique individuals were included in this analysis.
Cancer cases were identified based on claims in which at
least one diagnostic code indicated cancer and the procedure
performed was for cancer treatment with surgery, radiation
therapy, or chemotherapy. Incident cases were defined as
cancer cases diagnosed at least 60 days after the claim for
antiretroviral treatment. If more than one cancer diagnosis
was detected for an individual, this report includes the
cancer diagnosis from the first claim date. Incidence rates are
reported per 100,000 person-years.
Each individual’s duration of risk from cancer was from
the date of the initial antiretroviral claim until the termina-
tion of participation in the health plan. Duration of risk from
cancer was further divided by attained age: <30, 30–39, 40–
49, 50–59, or≥60 years of age. For example, an individual who
was 35 years of age at the initial HIV claim and terminated the
health plan at 42 years of age would contribute 5 years to the
cumulative duration of risk of those 30–39 years of age and 2
years to the cumulative duration of risk of those 40–49 years
of age.
For AIDS-defining cancers (ADCs) and non-AIDS-
defining cancers (NADCs) that occurred in at least 5% of the
cancer cases, incidence rates per 100,000 person-years and
their 95% Poisson confidence intervals were estimated. Pois-
son regression analyses were used to evaluate the association
of age group and gender on incidence rates.
To determine whether cancer incidence rates among
HIV-infected individuals differed from those for the general
population, the expected number of cases for each gender-age
group (<30, 30–39, 40–49, 50–59, and ≥60) were estimated
using incidence rates from the Surveillance Epidemiology
and End Results (SEER) program (http://seer.cancer.gov/).
Standardized incidence ratios were estimated using their 95%
confidence intervals. The Cochran-Armitage test was used to
evaluate the trends for the proportion of cancers that were
ADCs with age for each gender.
The studywas reviewed by the Institutional Review Board
(IRB) at the University of Arkansas for Medical Sciences.
The IRB determined that this study was not human subjects
research.
3. Results
This study included 50,960 men (80.6%) and 12,261 (19.4%)
women.The mean (SD) ages at initial claim for antiretroviral
therapy for men and women were 44.6 (9.6) years and 43.0
(9.8) years and their mean durations of participation in a
health care plan following initial antiretroviral claim were 3.7
(3.2) years and 3.9 (3.5) years, respectively. The number of
person-years at risk by gender and age group is summarized
in Table 1.
A total of 1,130 persons had at least one treatment
claim with a diagnosis of cancer: 978 men and 152 women.
The most frequently reported cancers were non-Hodgkin
lymphoma (NHL), Kaposi sarcoma (KS), anal cancer, and
prostate cancer (Table 2). Overall, 28.9% of cancers were
AIDS-defining. The proportion of cancers that were AIDS-
defining decreased with age for both men (𝑃 < 0.001) and
women (𝑃 < 0.001) (Figure 1). Among persons under 40
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Table 1: Person-years at risk by age group.
Age at risk (years) Person-years at risk
Women
Number of years (%)
Men
Number of years (%)
Total
Number of years (%)
<30 1752 (5.6) 5350 (4.1) 7102 (4.4)
30–39 7303 (23.5) 20775 (15.9) 28078 (17.4)
40–49 12140 (39.0) 55341 (42.4) 67481 (41.8)
50–59 7803 (25.1) 38303 (29.4) 46106 (28.5)
≥60 2111 (6.8) 10615 (8.1) 12726 (7.9)
Total 31109 (100.0) 130384 (100.0) 161493 (100.0)
Table 2: Cancer cases among HIV-infected persons.
Cancer site Female
𝑁 (%)
Male
𝑁 (%)
Total
𝑁 (%)
AIDS-defining cancer
Kaposi’s sarcoma 4 (2.6) 135 (13.8) 139 (12.3)
Non-Hodgkin’s lymphoma 26 (17.1) 156 (16.0) 182 (16.1)
Cervix 5 (3.3) — 5 (0.4)
Non-AIDS-defining cancer
Oropharynx 1 (0.7) 21 (2.2) 22 (2.0)
Colon/rectum 6 (4.0) 56 (5.7) 62 (5.5)
Liver 3 (2.0) 13 (1.3) 16 (1.4)
Pancreas 2 (1.3) 13 (1.3) 15 (1.3)
Anus 14 (9.2) 122 (12.5) 136 (12.0)
Larynx 0 12 (1.2) 12 (1.1)
Lung, bronchus 12 (7.9) 51 (5.2) 63 (5.6)
Skin excluding melanoma, basal, and squamous cell 2 (1.3) 32 (3.3) 34 (3.0)
Breast 40 (26.3) — 40 (3.5)
Bladder 4 (2.6) 24 (2.4) 28 (2.5)
Prostate — 119 (12.2) 119 (10.5)
Hodgkin’s lymphoma 4 (2.6) 53 (5.4) 57 (5.0)
Other 29 (19.1) 171 (17.5) 200 (17.7)
Total 152 978 1130
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Figure 1: Distribution of AIDS-defining cancers (ADCS) and non-AIDS-defining cancers (NADCs) among men (a) and women (b).
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years of age, the majority of cancers were ADCs. After 60
years of age, over 90% of the cancers were NADCs.
The incidence of non-Hodgkin lymphoma did not vary
by age or gender (Table 3). The incidence rates for Kaposi
sarcoma decreased with age with lower rates for those 60
years and older compared to those 30–59 years of age (𝑃 =
0.038) which, in turn, were significantly lower than the
incidence rates for persons under 30 years of age (𝑃 = 0.045).
KS occurred more frequently among men (IR = 103.5)
compared to women (IR = 12.9) (𝑃 < 0.001).
Anal cancer and Hodgkin lymphoma incidence rates
varied by gender, but not by age (Table 4). Incidence rates
for anal cancer were 93.6 and 45.0 for men and women,
respectively (𝑃 = 0.011), and for Hodgkin lymphoma were
40.6 and 12.9, respectively (𝑃 = 0.025). HIV-infected persons
60 years or older had higher incidence rates than those 30–59
years of age for colorectal (𝑃 = 0.003), lung (𝑃 < 0.001), and
prostate (𝑃 < 0.001) cancer.
As expected, incidence rates for KS and NHL were
elevated compared to those in the general population and
their SIRs declined with age. Incidence rates for anal cancer
and Hodgkin lymphoma were elevated and varied by gender.
SIRs for women and men were 15.66 (95% CI: 8.55 to 19.49)
and 34.3 (95%CI: 28.46 to 36.56) for anal cancer, respectively,
and 4.8 (95% CI: 1.28 to 7.56) and 10.7 (95% CI: 8.01 to 11.84)
for Hodgkin lymphoma, respectively.
For colorectal, lung, and prostate cancer, incidence rates
for HIV-infected persons were lower than those for the
general population. For lung and colorectal cancer, the SIRs
for persons 60 years and older were lower than those for
individuals who were 30–59 years of age.
4. Discussion
From our examination of the incidence of cancer among
privately insured HIV-infected adults in the US who were
receiving antiretroviral therapy, we made several observa-
tions. We confirmed that infection-related cancers, including
NHL, KS, and anal cancer, were themost commonly reported
cancers in this population. Consistent with previous reports,
we found that the incidence rates of noninfection related
NADCs such as colorectal and prostate cancer were lower
than those for the general population. Our finding that the
incidence rate of lung cancer was lower than in the general
population varies from previous reports. The proportion of
cancer cases in this study that was ADCs was lower than
previously reported [22–24]. Among HIV-infected cancer
cases, about half were ADCs in an Italian study [22], one-
third were ADCs in a single institution study in the US [23],
and 60% were ADCs in an Australian observational database
[24]. Our finding of the decline with age in the proportion
of cancers that are ADCs is consistent with reports on the
age-related decline in cancers attributable to infectious agents
[25, 26].
Incidence rates for KS in this study were similar to those
reported in other studies during the HAART era [4, 8].
Decreases in the incidence rate of KS have been observed
with the increasing use of HAART [6, 27, 28] and increases
in CD4+ cell counts [29, 30]. The increased risk of KS
among men was related to the higher prevalence of human
herpesvirus 8 infection, the etiologic agent of KS, among
MSM compared to other risk groups [30, 31]. The declining
incidence of KS associated with age observed in this study
has been described previously [32].
The incidence of NHL observed in this study was similar
to or lower than reported previously [4, 8]. Although a
gender disparity in NHL incidence was not observed in this
study, other reports showed that HIV-infected MSM have
the highest risk of NHL, followed by other men and women
[30].The risk of NHLwas inversely correlated with CD4+ cell
count [29, 30]. Like KS, the incidence of NHL has decreased
with time [6, 27, 28]. Although the incidence rates of both
NHL and KS have decreased with time [27]. HIV-infected
persons remain at elevated risk for both of these AIDS-
defining cancers.
Our HL incidence was similar to previous reports [8,
33, 34]. The gender difference in HL incidence is similar to
that reported in the general population [35]. There are mixed
reports on the association between CD4+ cell counts and risk
of HL amongHIV-infected persons.The incidence of HL was
positively correlated with CD4+ cell counts which suggests
that improvements in CD4+ lymphocyte counts related to
HAART use lead to an increasing risk of HL [33, 36]. Lower
CD4+ lymphocyte counts in the 1-2 years preceding HL
diagnosis were significantly associated with an elevated HL
risk in the Swiss HIV Cohort Study [37]. It has been reported
that HL incidence is highest in the 1–3 months following
HAART initiation and decreases but remains elevated 4–
6 months following HAART initiation [36]. Our finding
that HL incidence among HIV-infected persons was elevated
compared to the general population corroborates previous
reports [2, 6, 33, 38].
Our anal cancer incidence rate for men was between
the rates for MSM and other men reported in the North
American (NA) ACCORD study [39] but lower than those
from other reports [40–42]. Anal cancer incidence in women
was similar to that in the NA-ACCORD study [39]. Anal
cancer incidence rates among HIV-infected persons have
increased with time [27, 28].The SIR in this study was similar
to that reported previously [2, 6, 8].
Human papillomavirus (HPV) infection is causally
related to anal cancer. Among HIV-infected MSM, the
prevalence of analHPV is 77% andwas lower among those on
HAART [43]. AnalHPVprevalence in the general population
was 12.9% [44]. Among MSM, detection of anal HPV was
associated with receptive anal intercourse and number of
male sexual partners in the preceding 6 months [45]. Among
HIV-infected men, the prevalence of anal HPV-16, one of
the high risk HPV types, decreases with educational level
[46]. In a study of MSM, those with health insurance were
less likely to engage in unprotected anal intercourse with
male partners and had higher educational attainment than
their uninsured counterparts [47]. Since our participant
population was insured, the rate of anal cancer in men may
reflect a lower prevalence of anal HPV due to less risky sexual
behavior and higher educational attainment.
In our study, risks for cancers that are not infection-
relatedwere not elevated compared to the general population.
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The observed incidence of colorectal cancer does not differ
significantly from previous reports [29, 41]. The SIR was
consistent with that reported in a meta-analysis [2].
The lung cancer incidence rate among those 30–59
years old was lower compared to their older counterparts,
consistent with the increasing risk of lung cancer with age
in the general population [48]. Compared to the general
population, the incidence rate in the younger age group did
not differ significantly, but older HIV-infected persons had a
lower lung cancer incidence rate.
Our findings vary from reports of an elevated risk of
lung cancer associated with HIV [2, 5, 6, 8, 40, 41]. It has
been reported that HIV patients are not at elevated risk
after adjusting for smoking and other risk factors [29], but
other reports show that HIV is an independent risk factor
for lung cancer [5, 49]. HIV-infected persons are diagnosed
with lung cancer at earlier ages and at lower cumulative
smoking exposures than the general population [48, 50].
The decreased incidence of lung cancer in this study may
reflect a lower prevalence of smoking in our population. In
a study of MSM that measured health access using three
indicators based on primary care clinic visits in the preceding
2 years, current health insurance, and perceived barriers to
health care, smoking prevalence decreased with the increase
in positive health access indices [51]. Among adults in the
US, the proportion with private health insurance coverage
increases with educational level [16] and smoking prevalence
declines with educational level [52].
Reports on the role of immunosuppression in the
incidence of lung cancer are mixed. A report from the
French HIV Database Study reported an inverse relationship
between lung cancer risk and CD4 counts [30] and an
elevated risk of lung cancer was observed among HIV-
infected individuals with CD4+ cells counts below 200 𝜇L
in an integrated health care system in the US [29]. Other
studies did not show a correlation between CD4 count and
lung cancer risk [53, 54].
Our finding that prostate cancer incidence was reduced
in HIV-infected men confirms previous reports [55, 56].
Although it was suggested that the decreased incidence rate
was associated with a lowered use of the prostate-specific
antigen (PSA) test to screen for prostate cancer [55], a
comparison of HIV-infected and HIV-uninfected men in
California found no difference with respect to PSA screening
utilization [56].
As our case definition required an insurance claim for
cancer treatment, cancer cases that were not treated were
not included which may have underestimated the number of
cancer cases. It has been widely reported that HIV-infected
persons are less likely to receive treatment for cancer than
their immunocompetent counterparts [57–59]. The disparity
in receipt of treatment persists even among privately insured
cancer patients [57]. Among lung cancer patients with private
insurance, 23% of those infected with HIV and only 10% of
those who were uninfected with HIV were untreated [57].
This study has a number of limitations. Since the database
is one of administrative claims, the actual date of diagnosis
was unknown. Our use of the 60-day window between
initiation of antiretroviral use and cancer diagnosis may have
led to an undercounting of cancer cases. Individual level
information was not available for race/ethnicity, socioeco-
nomic status, education level, level of immune suppression,
or measures of sexual activity. The database did not allow
evaluation of the relationship between HAART, markers of
HIV disease, and cancer incidence.
This study in a population of commercially insured HIV-
infected persons treated with antiretroviral therapy found
elevated incidence rates for KS and NHL and infection-
related NADCs, anal cancer, and Hodgkin lymphoma. Inci-
dence rates for lung and colorectal cancer were not elevated
in this HIV-infected population. Similar to other studies,
prostate cancer incidence was lower among HIV-infected
men compared to the general population. Although privately
insured HIV-infected persons have greater access to health
care services and earlier exposure to antiretroviral therapy
(Schneider) and engage in fewer risky behaviors (McKirnan)
than those with public insurance or who lack insurance, this
did not appear to reduce the cancer incidence rates in this
population.
5. Conclusions
Commercially insured HIV-infected adults treated with
antiretroviral therapy were at greater risk of infection-
related cancers compared to the general population. Their
risk for common non-AIDS defining cancers of the lung,
colon/rectum, and prostate was not elevated.
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